Axsome Therapeutics Quarterly Balance Sheet
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Axsome Therapeutics financial position
As of Jun 30, 2026, Axsome Therapeutics reported total assets of $761.4 million, up 19.0% from a year earlier against total liabilities of $678.1 million. Shareholders' equity stood at $83.3 million, or 10.9% of assets. The company held $319.9 million in cash and equivalents against $188.0 million of debt, a net cash position of $131.9 million.
The current ratio (current assets divided by current liabilities) was 1.43, meaning short-term assets cover obligations due within a year. Debt-to-equity was 2.26.
Summary generated from market data by MetaCap's automated system. Methodology
Axsome Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 319.85M | 305.11M | 322.93M | 325.27M | 303.02M | 300.91M | 315.35M | 327.34M | 315.66M | 331.44M | 386.19M | 416.56M |
| Receivables | 277.46M | 251.06M | 224.46M | 196.51M | 198.82M | 161.40M | 142.00M | 124.10M | 120.34M | 101.43M | 94.82M | 78.42M |
| Inventory | 37.88M | 31.52M | 27.94M | 23.77M | 18.44M | 16.32M | 15.73M | 14.27M | 15.22M | 15.58M | 15.13M | 9.98M |
| Total Current Assets | 656.57M | 611.21M | 588.99M | 565.34M | 536.62M | 494.63M | 485.06M | 479.11M | 463.03M | 460.49M | 504.26M | 511.76M |
| Property, Plant & Equipment | 874.00K | 567.00K | 562.00K | 605.00K | 667.00K | 773.00K | 584.00K | 683.00K | 724.00K | 812.00K | 846.00K | 971.00K |
| Goodwill | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M | 12.04M |
| Intangible Assets | 37.36M | 38.95M | 40.52M | 42.13M | 43.73M | 45.32M | 46.89M | 48.50M | 50.11M | 51.70M | 53.29M | 54.89M |
| Total Assets | 761.45M | 713.61M | 689.80M | 669.25M | 639.78M | 596.67M | 568.50M | 561.46M | 548.23M | 545.73M | 588.24M | 600.86M |
| Accounts Payable | 78.97M | 106.70M | 65.54M | 54.23M | 91.63M | 85.66M | 72.00M | 64.25M | 61.34M | 53.79M | 40.68M | 29.10M |
| Short-Term Debt | 70.00M | 70.00M | 70.00M | 70.00M | 70.00M | — | 0 | — | — | — | — | — |
| Total Current Liabilities | 460.45M | 439.21M | 378.84M | 360.29M | 342.10M | 243.91M | 230.10M | 196.19M | 186.57M | 144.05M | 138.85M | 114.66M |
| Long-Term Debt | 117.96M | 117.85M | 117.75M | 117.64M | 117.54M | 181.38M | 180.71M | 180.00M | 179.33M | 178.69M | 178.07M | 177.45M |
| Total Liabilities | 678.14M | 659.02M | 601.51M | 595.52M | 566.71M | 543.47M | 511.48M | 468.56M | 445.37M | 401.69M | 397.26M | 331.35M |
| Shareholders' Equity | 83.30M | 54.59M | 88.30M | 73.73M | 73.08M | 53.20M | 57.02M | 92.90M | 102.85M | 144.04M | 190.98M | 269.51M |
| Retained Earnings | -1.42B | -1.37B | -1.31B | -1.28B | -1.23B | -1.18B | -1.12B | -1.05B | -983.27M | -903.93M | -835.57M | -736.92M |
| Total Debt | 187.96M | 187.85M | 187.75M | 187.64M | 187.54M | 181.38M | 180.71M | 180.00M | 179.33M | 178.69M | 178.07M | 177.45M |
| Net Cash (Debt) | 131.89M | 117.26M | 135.19M | 137.63M | 115.48M | 119.53M | 134.64M | 147.34M | 136.33M | 152.75M | 208.12M | 239.12M |
| Shares Outstanding | 52.30M | 51.42M | 50.88M | 50.31M | 49.82M | 49.22M | 48.67M | 48.44M | 47.80M | 47.46M | 47.35M | 47.32M |
This table shows 12 quarterly periods of Axsome Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AXSM's reporting calendar. What is a balance sheet?